{"id":"https://openalex.org/W3214727871","doi":"https://doi.org/10.1182/blood-2021-145569","title":"Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure","display_name":"Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure","publication_year":2021,"publication_date":"2021-11-05","ids":{"openalex":"https://openalex.org/W3214727871","doi":"https://doi.org/10.1182/blood-2021-145569","mag":"3214727871"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2021-145569","doi":"https://doi.org/10.1182/blood-2021-145569","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-145569","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5046827092","display_name":"Claire N. Harrison","orcid":"https://orcid.org/0000-0002-3212-920X","observed_orcids":["https://orcid.org/0000-0002-3212-920X"]},"institutions":[{"id":"https://openalex.org/I200166805","display_name":"Guy's and St Thomas' NHS Foundation Trust","ror":"https://ror.org/00j161312","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I200166805"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Claire N. Harrison","raw_affiliation_strings":["Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom","institution_ids":["https://openalex.org/I200166805"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072336042","display_name":"John O Mascarenhas","orcid":"https://orcid.org/0000-0002-8400-0483","observed_orcids":["https://orcid.org/0000-0002-8400-0483"]},"institutions":[{"id":"https://openalex.org/I4390039328","display_name":"Tisch Cancer Institute","ror":"https://ror.org/0317dzj93","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1320796813","https://openalex.org/I4390039328","https://openalex.org/I98704320"]},{"id":"https://openalex.org/I98704320","display_name":"Icahn School of Medicine at Mount Sinai","ror":"https://ror.org/04a9tmd77","country_code":"US","type":"education","lineage":["https://openalex.org/I1320796813","https://openalex.org/I98704320"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Mascarenhas","raw_affiliation_strings":["The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY","institution_ids":["https://openalex.org/I4390039328","https://openalex.org/I98704320"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113907832","display_name":"Pranav Abraham","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pranav Abraham","raw_affiliation_strings":["Bristol Myers Squibb, Lawrenceville, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Lawrenceville, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000778444","display_name":"Arianna Kee","orcid":"https://orcid.org/0000-0001-8195-0224","observed_orcids":["https://orcid.org/0000-0001-8195-0224"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Arianna Kee","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035727807","display_name":"Jose Alberto Nadal","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jose Alberto Nadal","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017590732","display_name":"Alexandrina Balanean","orcid":"https://orcid.org/0000-0001-5540-0755","observed_orcids":["https://orcid.org/0000-0001-5540-0755"]},"institutions":[{"id":"https://openalex.org/I4210150323","display_name":"Cardinal Health (United States)","ror":"https://ror.org/03pd82777","country_code":"US","type":"company","lineage":["https://openalex.org/I4210150323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexandrina Balanean","raw_affiliation_strings":["Cardinal Health Specialty Solutions, Dublin, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cardinal Health Specialty Solutions, Dublin, OH","institution_ids":["https://openalex.org/I4210150323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049387929","display_name":"Ali McBride","orcid":"https://orcid.org/0000-0002-9430-4675","observed_orcids":["https://orcid.org/0000-0002-9430-4675"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ali McBride","raw_affiliation_strings":["Bristol Myers Squibb, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol Myers Squibb, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006893148","display_name":"Jonathan Karl Kish","orcid":"https://orcid.org/0000-0002-2824-8468","observed_orcids":["https://orcid.org/0000-0002-2824-8468"]},"institutions":[{"id":"https://openalex.org/I4210150323","display_name":"Cardinal Health (United States)","ror":"https://ror.org/03pd82777","country_code":"US","type":"company","lineage":["https://openalex.org/I4210150323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan K. Kish","raw_affiliation_strings":["Cardinal Health Specialty Solutions, Dublin, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cardinal Health Specialty Solutions, Dublin, OH","institution_ids":["https://openalex.org/I4210150323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084076545","display_name":"Djibril Liassou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150323","display_name":"Cardinal Health (United States)","ror":"https://ror.org/03pd82777","country_code":"US","type":"company","lineage":["https://openalex.org/I4210150323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Djibril Liassou","raw_affiliation_strings":["Cardinal Health Specialty Solutions, Dublin, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cardinal Health Specialty Solutions, Dublin, OH","institution_ids":["https://openalex.org/I4210150323"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050866878","display_name":"Bruce A. Feinberg","orcid":"https://orcid.org/0000-0001-9267-9994","observed_orcids":["https://orcid.org/0000-0001-9267-9994"]},"institutions":[{"id":"https://openalex.org/I4210150323","display_name":"Cardinal Health (United States)","ror":"https://ror.org/03pd82777","country_code":"US","type":"company","lineage":["https://openalex.org/I4210150323"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bruce A. Feinberg","raw_affiliation_strings":["Cardinal Health Specialty Solutions, Dublin, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cardinal Health Specialty Solutions, Dublin, OH","institution_ids":["https://openalex.org/I4210150323"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5023728016","display_name":"Aaron Thomas Gerds","orcid":"https://orcid.org/0000-0002-3422-1309","observed_orcids":["https://orcid.org/0000-0002-3422-1309"]},"institutions":[{"id":"https://openalex.org/I1316902750","display_name":"Cleveland Clinic","ror":"https://ror.org/03xjacd83","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316902750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Aaron T. Gerds","raw_affiliation_strings":["Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cleveland Clinic Taussig Cancer Institute, Cleveland, OH","institution_ids":["https://openalex.org/I1316902750"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"138","issue":"Supplement 1","first_page":"3059","last_page":"3059"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fedratinib","display_name":"fedratinib","score":0.9800000190734863},{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.9240000247955322},{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.8560000061988831},{"id":"https://openalex.org/keywords/treatment-patterns","display_name":"treatment patterns","score":0.6669999957084656},{"id":"https://openalex.org/keywords/dose-reduction","display_name":"dose reduction","score":0.4020000100135803},{"id":"https://openalex.org/keywords/dose-interruption","display_name":"dose interruption","score":0.43700000643730164},{"id":"https://openalex.org/keywords/spleen-size","display_name":"spleen size","score":0.6650000214576721},{"id":"https://openalex.org/keywords/jak2-v617f-mutation","display_name":"JAK2 V617F mutation","score":0.8339999914169312},{"id":"https://openalex.org/keywords/calr-mutation","display_name":"CALR mutation","score":0.6060000061988831},{"id":"https://openalex.org/keywords/real-world-data","display_name":"real-world data","score":0.5550000071525574},{"id":"https://openalex.org/keywords/community-oncology-practice","display_name":"community oncology practice","score":0.6830000281333923},{"id":"https://openalex.org/keywords/primary-myelofibrosis","display_name":"primary myelofibrosis","score":0.6010000109672546},{"id":"https://openalex.org/keywords/secondary-myelofibrosis","display_name":"secondary myelofibrosis","score":0.9589999914169312}],"concepts":[{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.9111016988754272},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8809127807617188},{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.8649652004241943},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5734507441520691},{"id":"https://openalex.org/C2780240888","wikidata":"https://www.wikidata.org/wiki/Q6052586","display_name":"International Prognostic Scoring System","level":4,"score":0.48619765043258667},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4109702706336975},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.355629563331604},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.28823286294937134},{"id":"https://openalex.org/C2780817109","wikidata":"https://www.wikidata.org/wiki/Q954625","display_name":"Myelodysplastic syndromes","level":3,"score":0.2168731391429901},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2021-145569","doi":"https://doi.org/10.1182/blood-2021-145569","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2021-145569","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4283319553","https://openalex.org/W4387122203","https://openalex.org/W4389222216","https://openalex.org/W4402479687","https://openalex.org/W4406852237","https://openalex.org/W3215427420","https://openalex.org/W3096039995","https://openalex.org/W3213543135","https://openalex.org/W4406367426","https://openalex.org/W4402346966"],"abstract_inverted_index":{"Abstract":[0],"Introduction:":[1],"In":[2],"August":[3,67],"2019,":[4],"fedratinib":[5],"(FEDR)":[6],"became":[7],"the":[8,110,152,158,424,451,456,597,618,652],"second":[9],"treatment":[10,40,182,295,626],"(in":[11],"addition":[12],"to":[13,16,208,326,328,340,447,471],"ruxolitinib":[14],"[RUX])":[15],"be":[17,672],"approved":[18],"for":[19,44,180,191,258,307,392,453,514,605,674],"intermediate-":[20,57],"or":[21,24,58,65,176,201,206,401,435,494,694,711,724,737,750,765,778,791,808,825,838,851,865,880,903,917,931,945,963,975,989,1003,1017,1030,1047,1060,1072,1084],"high-risk":[22,59],"primary":[23,234],"secondary":[25],"myelofibrosis":[26],"(MF).":[27],"No":[28],"real-world":[29],"data":[30],"(RWD)":[31],"have":[32,448],"been":[33],"presented":[34],"on":[35,64,358,688,705,718,731,744,759,772,785,802,819,832,845,859,874,897,911,925,939,957,969,983,997,1011,1024,1041,1054,1066,1078],"demographics,":[36],"clinical":[37,128],"characteristics,":[38],"and":[39,92,119,132,135,166,178,198,241,272,299,319,332,345,382,405,440,479,497,540,561,594,625,634,644,648,1119],"patterns":[41],"of":[42,80,90,101,224,260,266,304,351,394,420,426,437,463,468,485,516,522,547,550,607,622,641,654,661,666,669,692,709,722,735,748,763,776,789,806,823,836,849,863,878,901,915,929,943,961,973,987,1001,1015,1028,1045,1058,1070,1082],"FEDR":[43,47,63,83,136,507,519,575,611,635,655],"patients":[45,118,225,267,352,445,523,551,608],"receiving":[46,610],"per":[48,157,184],"US":[49],"label":[50],"post":[51,82],"RUX":[52,134,181,192,209,248,263,287,359,395,454,486,632,642,670],"failure.":[53],"Methods:":[54],"Adults":[55],"with":[56,76,410,504,658,677],"MF":[60,334,433,464,629],"who":[61,93],"initiated":[62,509],"after":[66,73],"16,":[68],"2019":[69],"(FEDR":[70],"approval":[71],"date)":[72],"discontinuing":[74],"RUX,":[75],"\u2264":[77],"90":[78],"days":[79],"follow-up":[81],"initiation":[84,100,249,546,576,656,660],"(and":[85],"having":[86],"completed":[87,120],"\u22651":[88],"cycle":[89],"FEDR)":[91],"had":[94,233,268,274,524,552,638,645],"a":[95,196,255],"spleen":[96,148,421,469,556,647],"size":[97,149,422,470,557],"assessment":[98],"at":[99,130,218,247,510,574,651,659,664],"FEDR,":[102,548],"were":[103,187,194,226,229,237,243,288,309,324,338,603],"identified":[104],"from":[105,628],"community":[106],"oncology":[107],"practices":[108],"in":[109,290,297,302,432,1133],"USA.":[111],"The":[112],"patients'":[113],"treating":[114],"physicians":[115],"selected":[116],"eligible":[117,214],"electronic":[121],"case":[122],"report":[123,186],"forms.":[124],"Providers":[125],"abstracted":[126],"patient":[127,316,346,623],"characteristics":[129,624],"diagnosis":[131,219,630],"during":[133,286,612],"therapy,":[137],"including":[138,360],"bone":[139,589],"marrow":[140],"fibrosis":[141],"grade,":[142],"biomarkers,":[143],"risk":[144,543,665],"score,":[145],"performance":[146],"status,":[147],"(centimeters":[150],"above":[151],"costal":[153],"margin),":[154],"symptoms":[155,335,434,465],"(listing":[156],"Modified":[159],"Myelofibrosis":[160],"Symptom":[161],"Assessment":[162],"Form":[163],"version":[164],"4.0),":[165],"complete":[167],"blood":[168,649],"count":[169,279,564],"data.":[170],"Dose,":[171],"dose":[172,300,330],"modifications":[173,602],"(reductions,":[174],"interruptions,":[175],"increases),":[177],"dates/rationale":[179],"failure":[183,193,668],"provider":[185],"collected.":[188],"Primary":[189,390],"reasons":[190,442,481],"designated":[195],"priori":[197],"included":[199,577],"refractory":[200,400,411,427,493],"suboptimal":[202,402],"response,":[203,412],"disease":[204,397,428,505],"progression,":[205],"intolerance":[207,406],"therapy.":[210],"Results:":[211],"For":[212],"150":[213],"patients,":[215,496],"median":[216,562],"age":[217],"was":[220,250,280,396,461,487,508,558,565],"68":[221],"years,":[222],"55%":[223,236],"male,":[227],"68%":[228],"non-Hispanic":[230],"White,":[231],"85%":[232],"MF,":[235],"JAK2":[238],"V617F":[239],"positive,":[240],"9%":[242],"JAK2/MPL/CALR":[244],"negative.":[245],"Dose":[246,284,322,601],"\u2265":[251,365,372,379,387],"20":[252],"mg":[253,512],"twice":[254],"day":[256],"(bid)":[257],"50%":[259,473],"patients.":[261,305,517],"At":[262,518,545],"initiation,":[264,520],"65%":[265],"ECOG":[269],"0/1":[270],"scores,":[271],"90%":[273],"palpable":[275,553],"spleen.":[276],"Median":[277,483],"platelet":[278,563],"118":[281],"\u00d710":[282],"9/L.":[283],"reductions":[285,308],"reported":[289,416,573],"13%":[291],"(n":[292],"=":[293],"19),":[294],"interruptions":[296],"3%,":[298],"increases":[301,323],"12%":[303],"Rationale":[306],"neutropenia":[310,343],"(7/19),":[311],"thrombocytopenia":[312,341,361],"(6/19),":[313],"other":[314,441,480],"(3/19),":[315],"request":[317,347],"(2/19),":[318],"anemia":[320,368],"(1/19).":[321],"due":[325,339],"titration":[327],"therapeutic":[329],"(13/18)":[331],"persistent":[333],"(5/18).":[336],"Interruptions":[337],"(2/4),":[342],"(1/4),":[344],"(1/4).":[348],"Overall":[349],"37%":[350],"experienced":[353],"an":[354,689,706,719,732,745,760,773,786,803,820,833,846,860,875,898,912,926,940,958,970,984,998,1012,1025,1042,1055,1067,1079],"adverse":[355],"event":[356],"while":[357,609],"(25":[362],"total;":[363],"4":[364],"grade":[366,373,380,388],"3),":[367,374],"(24":[369,376],"total,":[370,377,385],"3":[371],"fatigue":[375,578],"1":[378,386,680],"3)":[381],"nausea":[383],"(10":[384],"3).":[389],"rationale":[391,452],"discontinuation":[393],"progression":[398,449],"(70%),":[399],"response":[403,477],"(25%),":[404,588],"(5%).":[407],"Among":[408,444],"those":[409,503],"providers":[413],"most":[414,457],"commonly":[415],"<":[417],"25%":[418],"reduction":[419],"as":[423,450],"indicator":[425],"(46%),":[429],"no":[430],"improvement":[431],"quality":[436],"life":[438],"(32%),":[439],"(22%).":[443],"deemed":[446],"discontinuation,":[455],"common":[458],"reason":[459],"cited":[460],"return":[462],"(65%),":[466],"increase":[467],">":[472],"versus":[474],"best":[475],"achieved":[476],"(23%),":[478],"(12%).":[482],"duration":[484,640],"4.4":[488],"(range":[489,499],"1-21)":[490],"months":[491,501],"among":[492,502],"intolerant":[495],"14":[498],"2-65)":[500],"progression.":[506],"400":[511],"bid":[513],"74%":[515],"43.3%":[521],"International":[525],"Prognostic":[526],"Scoring":[527],"System":[528],"(IPSS)/":[529],"Dynamic":[530],"IPSS":[531],"(DIPSS)":[532],"High-risk,":[533],"36.7%":[534],"Intermediate":[535],"(Int)-2":[536],"risk,":[537],"9.3%":[538],"Int-1,":[539],"10.0%":[541],"unknown":[542],"(Table).":[544],"88%":[549],"spleen,":[554],"mean":[555],"16":[559],"cm,":[560],"98":[566],"\u00d7":[567],"10":[568],"9/L":[569],"(Table":[570],"1).":[571],"Symptoms":[572],"(72%),":[579],"abdominal":[580],"discomfort":[581],"(51%),":[582],"night":[583],"sweats":[584],"(44%),":[585],"early":[586,667],"satiety":[587],"pain":[590,595],"(18%),":[591],"itching":[592],"(13%),":[593],"under":[596],"left":[598],"rib":[599],"(13%).":[600],"observed":[604],"6%":[606],"follow-up.":[613],"Conclusions:":[614],"This":[615],"study":[616],"represents":[617],"first":[619],"RWD":[620],"description":[621],"journey":[627],"through":[631],"therapy":[633,643],"treatment.":[636],"Patients":[637,663],"shorter":[639],"poorer":[646],"counts":[650],"time":[653],"compared":[657],"RUX.":[662],"should":[671],"considered":[673],"earlier":[675],"intervention":[676],"FEDR.":[678],"Figure":[679,681],"1.":[682],"Disclosures":[683],"Harrison:":[684],"CTI":[685,1020,1165],"BioPharma:":[686,1166],"Membership":[687,704,717,730,743,758,771,784,801,818,831,844,858,873,896,910,924,938,956,968,982,996,1010,1023,1040,1053,1065,1077],"entity's":[690,707,720,733,746,761,774,787,804,821,834,847,861,876,899,913,927,941,959,971,985,999,1013,1026,1043,1056,1068,1080],"Board":[691,708,721,734,747,762,775,788,805,822,835,848,862,877,900,914,928,942,960,972,986,1000,1014,1027,1044,1057,1069,1081],"Directors":[693,710,723,736,749,764,777,790,807,824,837,850,864,879,902,916,930,944,962,974,988,1002,1016,1029,1046,1059,1071,1083],"advisory":[695,712,725,738,751,766,779,792,809,826,839,852,866,881,904,918,932,946,964,976,990,1004,1018,1031,1048,1061,1073,1085],"committees,":[696,713,726,739,752,767,780,793,810,827,840,853,867,882,905,919,933,947,977,991,1005,1032],"Speakers":[697,714,727,740,753,768,781,794,798,811,828,841,854,870,885],"Bureau;":[698,715,728,741,754,769,782,795,799,812,829,842,855,871],"Sierra":[699,1050,1154],"Oncology:":[700,1051,1155],"Honoraria;":[701],"Gilead":[702],"Sciences:":[703],"Shire:":[716],"Geron:":[729,892,950],"Keros:":[742],"AOP":[755],"Orphan":[756],"Pharmaceuticals:":[757,814],"Promedior:":[770,1075],"Abbvie:":[783],"Incyte":[796],"Corporation:":[797,1150],"BMS:":[800,1122],"Constellation":[813],"Research":[815,868,883,906,920,934,948,952,978,992,1006,1033,1036,1088,1136,1167],"Funding;":[816,907,921,935,949,953,979,993,1007,1034,1037],"Roche:":[817,922],"Janssen:":[830],"Galacteo:":[843],"Celgene:":[856],"Honoraria,":[857],"Funding,":[869,884],"Novartis:":[872,936,1152],"Bureau.":[886],"Mascarenhas:":[887],"Galecto:":[888],"Consultancy;":[889,891,893,1151,1153,1156,1158,1162,1164],"Prelude:":[890],"PharmaEssentia:":[894],"Consultancy,":[895,909,923,937,951,955,967,981,995,1009,1022,1039,1052,1064,1076],"Incyte:":[908],"Genentech/Roche:":[954],"committees;":[965,1019,1049,1062,1074,1086],"Kartos:":[966],"Merck:":[980],"AbbVie:":[994,1157],"Constellation:":[1008,1163],"Biopharm:":[1021],"Forbius:":[1035],"Celgene/BMS:":[1038],"Gilead:":[1063],"Merus:":[1087],"Funding.":[1089,1137,1168],"Abraham:":[1090],"Bristol":[1091,1097,1103],"Myers":[1092,1098,1104,1160],"Squibb:":[1093,1099,1105,1161],"Current":[1094,1100,1106,1111,1123,1128,1130,1141,1146],"Employment.":[1095,1101,1107,1124,1142,1147],"Kee:":[1096],"Nadal:":[1102],"Balanean:":[1108],"Cardinal":[1109,1126,1139,1144],"Health:":[1110,1127,1140,1145],"Employment;":[1112],"Georgia":[1113],"State":[1114],"University:":[1115],"Other:":[1116],"former":[1117],"student":[1118],"employee.":[1120],"McBride:":[1121],"Kish:":[1125],"Employment,":[1129],"equity":[1131],"holder":[1132],"publicly-traded":[1134],"company,":[1135],"Liassou:":[1138],"Feinberg:":[1143],"Gerds:":[1148],"PharmaEssentia":[1149],"Celgene/Bristol":[1159]},"counts_by_year":[{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2021-11-22T00:00:00"}